Beigene Ltd (NASDAQ:BGNE) shares rose 5.1% on Wednesday after Morgan Stanley raised their price target on the stock from $93.00 to $200.00. Morgan Stanley currently has an overweight rating on the stock. Beigene traded as high as $177.00 and last traded at $180.90. Approximately 365,590 shares traded hands during trading, a decline of 5% from the average daily volume of 384,547 shares. The stock had previously closed at $172.17.

Several other brokerages also recently commented on BGNE. Maxim Group set a $120.00 target price on shares of Beigene and gave the stock a “buy” rating in a report on Monday, December 11th. Cowen reiterated a “buy” rating on shares of Beigene in a report on Monday, December 11th. ValuEngine downgraded shares of Beigene from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a report on Monday, January 8th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Beigene currently has a consensus rating of “Buy” and a consensus price target of $145.17.

How to Become a New Pot Stock Millionaire

In related news, Director Bros. Advisors Lp Baker acquired 1,980,198 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were bought at an average price of $101.00 per share, for a total transaction of $199,999,998.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John Oyler sold 20,137 shares of the business’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $96.46, for a total transaction of $1,942,415.02. Following the transaction, the chief executive officer now owns 110,179 shares in the company, valued at approximately $10,627,866.34. The disclosure for this sale can be found here. Insiders sold a total of 214,347 shares of company stock worth $30,984,091 in the last quarter. Insiders own 19.90% of the company’s stock.

Large investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in shares of Beigene during the 3rd quarter worth about $160,000. Tower Research Capital LLC TRC bought a new position in shares of Beigene during the 4th quarter worth about $182,000. Comerica Bank acquired a new stake in shares of Beigene during the 4th quarter valued at about $246,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Beigene during the 3rd quarter valued at about $248,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Beigene during the 4th quarter valued at about $250,000. Institutional investors own 51.47% of the company’s stock.

The company has a current ratio of 6.09, a quick ratio of 6.02 and a debt-to-equity ratio of 0.23. The company has a market cap of $9,222.29, a PE ratio of -67.37 and a beta of 0.58.

Beigene (NASDAQ:BGNE) last issued its earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.40). The firm had revenue of $18.17 million for the quarter, compared to analyst estimates of $23.00 million. equities analysts expect that Beigene Ltd will post -7.69 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Beigene (BGNE) Stock Price Up 5.1% on Analyst Upgrade” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/beigene-bgne-stock-price-up-5-1-on-analyst-upgrade/1958812.html.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.